This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. The company also expects revenue from all of 2024 to be $45 billion, lower than the range of $45.4 billion in revenue, less than the $13.9
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Megablockbusters are the holy grail.
On December 20, 2024, tirzepatide also received FDA approval for obstructive sleep apnea. Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four additional indications, including chronic kidney disease. While Wegovy caused an average weight loss of 13.7
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.
2024 study [16]. Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. 2024 Oct 8:S0735-6757(24)00523-0. Published online September 4, 2024. 2024.10.006].
Accretion Pharmaceuticals manufactures medicines for the treatment of a variety of conditions, including cardiovascular, anti-diabetic, anti-fungal, anti-allergic, pain management, vitamins and nutrition, anti-bacterials, anti-ulcerants, and neuropathy management. crore in the fiscal year 2024. The company has registered 35.66
Critical Timelines: Performance Year 2024: Providers must track and manage quality metrics from January 1 to December 31, 2024, focusing on key areas such as medication adherence and hospital readmission rates. Providers that meet these standards earn shared savings, a key financial benefit.
Since implementing the technology in April 2024, 86% of users report less burnout, 83% report improved work-life balance and job satisfaction, 80% report better patient experience, and 3 in 4 say they are less likely to leave clinical practice. based AdventHealth are using Nuance’s DAX Copilot ambient AI scribe. minutes to 35.4
In order to cover a large category of medicines, 29 Major therapeutic groups like antibiotics and anti-infectives, anti-cancer, anti-diabetics, cardiovascular drugs, analgesics and antipyretic, anti-allergic, gastro-intestinal agents, vitamins and minerals, food supplements/nutraceuticals, topical medicines etc have been covered in PMBJP basket.
Estimates vary for how many patients with either obesity or diabetes stop using the drugs, but one 2024 study pegged the discontinuation between 50% and 75% within a year. Discontinuation rates soar The high rate of discontinuation among GLP-1 users remains a prime burden to keeping patients on the drugs.
Examples include: Guide to Antimicrobial Therapy in the Adult ICU, 2023 ICU Management Protocols, 2019 Pediatric Protocols for Malaysian Hospitals, 2019 Practical Guide to Insulin Therapy in Type 2 Diabetes Mellitus, 2024 For daily practice, healthcare professionals may also refer to international guidelines such as GOLD , GINA , KDIGO , ESPEN and (..)
Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. per cent from 2024 to 2030. billion in 2023 and is expected to grow at a CAGR of 8.4 Whereas the global vitamin supplements market size was estimated at $48.51 per cent from 2023 to 2030.
14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.
Methodology for Safe and Secure AI in Diabetes Management. Internet] 2024. “Explainambiguity:” When What You Think Is Not What You Get. Internet] Life Science Leader. cited 2025Feb]. Available from: [link] Gioia V, Geukes Foppen RJ. Correct But Misleading: AI Hallucinations In Complex Decision-Making [Internet] Life Science Leader.
help teams generate draft copy, A/B test headlines, and adapt content across therapeutic areas—whether it’s for Dupixent in dermatology or Ozempic in diabetes care. A 2024 report by McKinsey found that personalized, AI-driven healthcare campaigns had 3x higher engagement rates than traditional strategies.
5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Deaths were reported in 5 TN and 6 R/R patients. The trial enrolled 598 patients 65 years or older with TN MCL. Hemasphere.
Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. 2 From October 2024 to March 2025, the CDC reported at least 37 million influenza infections, 480,000 hospitalizations, and 21,000 deaths.
And if you can do that, cancer becomes a chronic, manageable disease, like diabetes, cardiac disease or HIV. Everyones focused on killing the tumor and the goal should really be to prevent the tumor from killing the patient,” Zeskind said. I think we have to control cancer before we cure it.”
Factors driving the growth of FDCs One of the primary reasons for the rise of FDCs has been their role in addressing diseases that require multi-drug therapy, such as tuberculosis, cardiovascular conditions, diabetes, and infectious diseases. Rifampicin + Isoniazid + Ethambutol) Antimalarial combinations (e.g.,
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Unlike traditional celebrity endorsements, patient influencers often share their real struggles, treatments, and day-to-day management of conditions such as diabetes, lupus, Crohns disease, or cystic fibrosis. Chris Ruden Amputee and diabetic athlete promoting disability inclusion.
One of the most transformative areas they are leading is in the management of diabetes, particularly through continuous glucose monitors (CGMs) and wearable technologies. For individuals with diabetes, CGMs provide real-time data, allowing for earlier intervention and prevention of glycemic emergencies.
Updated April 2, 2024. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). Accessed June 24, 2025.
The FDA approved nemolizumab in December 2024 for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not controlled by topical prescription therapies among individuals 12 and older. May 15, 2024. December 16, 2024. June 6, 2025.
2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. A comprehensive evaluation of asthma therapy within a large healthcare system. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Charlotte, NC; June 9, 2025. Global Initiative for Asthma. Accessed June 9, 2025.
Since launching the service in September 2024, they’ve dispensed more than 300 boxes, with an estimated 72% acceptance rate. When patients are prescribed an opioid for the first time, the system alerts staff for a clinical consult. 1 This service can not only expand pharmacies’ clinical offerings but serves a crucial public health benefit.
Updated November 14, 2024. Updated October 31, 2024. Lastly, pharmacists should consider offering mail-back envelopes at no charge to provide patients with a convenient and secure alternative to other disposal options. REFERENCES 1. The impact of pharmaceuticals released to the environment. Accessed June 6, 2025. 2020;6(7):e04551.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models.
Updated September 10, 2024. TOC services are one of many areas where pharmacy models can improve patient outcomes, quality metrics, and hospital revenue. 4-6 Since this study’s completion, the institution has expanded its protocol with additional prescribing opportunities for TOC pharmacists and plans to expand services to non-HRRP patients.
September 11, 2024. Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. News release. Accessed June 18, 2025.
2024 ESC guidelines for the management of elevated blood pressure and hypertension. J Am Coll Cardiol. 2018;71:e127-e248. doi:10.1016/j.jacc.2017.11.006 2017.11.006 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021–3104. Eur Heart J.
1 The current post hoc secondary analysis was conducted from March to June 2024 and aimed to further evaluate the spillover of an audit-and-feedback intervention that targets individuals aged 65 and older on a broader population of all age groups.
For example, long-acting formulations, less painful injection methods, and fixed-dose combination therapies have each played a critical role in improving adherence and outcomes in conditions such as diabetes, autoimmune diseases, and HIV. 95 (May 15, 2025): 20674, https ://www.federalregister.gov/d/2025-08607. Joseph Mattingly II, Anthony A.
FluMist (live intranasal influenza vaccine; AstraZeneca) was approved in September 2024 for self- and caregiver administration for individuals aged 2 to 49 years. 8 This percentage is lower than the previous season (53%), which contributed to 250 pediatric deaths during the 2024-2025 influenza season. September 17, 2024.
New Hope: Finerenone and the FINEARTS-HF Trial The 2024 release of the FINEARTS-HF (NCT04435626) trial data has renewed attention on finerenone, which has shown promise in patients with mildly reduced or pEF. Unlike the steroidal MRAs spironolactone and eplerenone, finerenone is nonsteroidal and may offer better tolerability and adherence.
Last Updated November 11, 2024. Risk Evaluation and Mitigation Strategies | REMS. Last Updated May 20, 2025. Accessed June 30, 2025. American Cancer Society. CAR T-cell therapy and its side effects. Accessed June 30, 2025.
Updated June 20, 2024. 2024 US Generic & Biosimilar Medicines Savings Report. September 2024. This direct engagement is crucial in building confidence in biosimilars and ensuring their appropriate utilization, contributing to more affordable and accessible health care. REFERENCES 1. Accessed May 13, 2025. JAMA Health Forum.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content